Investigational drug · Phase 3
Inhaled Treprostinil
Also called: LIQ861 Inhaled Treprostinil, Inhaled prostacyclin
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
3 still active
All registered trials
57
Any phase or sponsor naming "Inhaled Treprostinil"
First trial start
2019
Jul 18, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Inhaled Treprostinil", any sponsor or status.
Conditions studied
As listed on its trial records.
- Interstitial Lung Disease
- Idiopathic Pulmonary Fibrosis
- Progressive Pulmonary Fibrosis
- Primary Pulmonary Hypertension
Approved drugs for the same conditions: High blood pressure (hypertension) · Idiopathic pulmonary fibrosis · Cardiovascular and metabolic · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "Inhaled Treprostinil" as an intervention, largest first.
- Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung DiseasePivotal-lookingEnrolling by invitation
United TherapeuticsIndustry
NCT04905693 · 1,850 participants (planned) · Start Sep 6, 2022 · Primary completion Dec 2029
Drug: Inhaled Treprostinil · For: Idiopathic Pulmonary Fibrosis; Interstitial Lung Disease; Progressive Pulmonary Fibrosis
Sites: Birmingham, Alabama; Franklin, Arizona; Phoenix, Arizona · 192 sites in all
United TherapeuticsIndustry
NCT01266265 · 1,333 participants · Start Dec 2010 · Primary completion Dec 2014
Drug: inhaled prostacyclin; inhaled prostacyclin and 4 more · For: Pulmonary Arterial Hypertension
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 88 sites in all
- A Study to Assess the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Progressive Pulmonary Fibrosis (PPF)Pivotal-lookingRecruiting
Insmed IncorporatedIndustry
NCT07805785 · 800 participants (planned) · Start Dec 1, 2026 · Primary completion Aug 31, 2030
Drug: Treprostinil Palmitil Inhalation Powder; Placebo · For: Progressive Pulmonary Fibrosis; Interstitial Lung Disease
Sites: DuBois, Pennsylvania
- Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)Pivotal-lookingRecruiting
United TherapeuticsIndustry
NCT05943535 · 698 participants (planned) · Start Oct 30, 2023 · Primary completion Nov 2027
Drug: Placebo; Inhaled Treprostinil · For: Progressive Pulmonary Fibrosis; Interstitial Lung Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 165 sites in all
- Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary FibrosisPivotal-lookingCompleted
United TherapeuticsIndustry
NCT04708782 · 598 participants · Start Apr 21, 2021 · Primary completion Feb 2, 2026
Drug: Placebo; Inhaled Treprostinil · For: Idiopathic Pulmonary Fibrosis; Interstitial Lung Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 96 sites in all
- Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary FibrosisPivotal-lookingCompleted
United TherapeuticsIndustry
NCT05255991 · 597 participants · Start Sep 12, 2022 · Primary completion Jun 30, 2025
Drug: Placebo; Inhaled Treprostinil · For: Idiopathic Pulmonary Fibrosis; Interstitial Lung Disease
Sites: Ciudad Autonoma de Buenos Aires, Argentina; Mar del Plata, Argentina; Córdoba, Argentina · 108 sites in all
- An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)Pivotal-lookingRecruiting
Insmed IncorporatedIndustry
NCT07234032 · 344 participants (planned) · Start Jul 20, 2026 · Primary completion Jan 22, 2031
Drug: Treprostinil Palmitil Inhalation Powder; Placebo · For: Pulmonary Hypertension; Interstitial Lung Disease
Sites: Naples, Florida; Bend, Oregon; Prague, Czechia · 12 sites in all
- Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)Pivotal-lookingRecruiting
Insmed IncorporatedIndustry
NCT07179380 · 344 participants (planned) · Start Jan 7, 2026 · Primary completion Dec 30, 2028
Drug: Treprostinil Palmitil Inhalation Powder; Placebo · For: Pulmonary Hypertension; Interstitial Lung Disease
Sites: Phoenix, Arizona; Fresno, California; Los Angeles, California · 186 sites in all
- A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILDPivotal-lookingRecruiting
Liquidia Technologies, Inc.Industry
NCT07285655 · 344 participants (planned) · Start Apr 23, 2026 · Primary completion Jul 2029
Drug: L606; Placebo · For: Pulmonary Hypertension Due to Lung Disease (Disorder)
Sites: Phoenix, Arizona; Scottsdale, Arizona; Los Angeles, California · 44 sites in all
- A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)Pivotal-lookingRecruiting
Insmed IncorporatedIndustry
NCT07481981 · 344 participants (planned) · Start Jul 21, 2026 · Primary completion Dec 28, 2028
Drug: Treprostinil Palmitil Inhalation Powder; Placebo · For: Pulmonary Arterial Hypertension
Sites: Los Angeles, California; Santa Barbara, California; Torrance, California · 39 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Idiopathic pulmonary fibrosis: Five trials to watch.
Koudstaal T, Verwaerde S, Moor CC, et al. · Med 2026
- A plain language review of the TETON-1 and TETON-2 studies: inhaled treprostinil (Tyvaso) in idiopathic pulmonary fibrosis.
Hwang S, Fuentes M, Lederer J, et al. · Expert Rev Respir Med 2026
- Transition From Continuous Intravenous to Inhaled Treprostinil: A Case of Refractory Pulmonary Arterial Hypertension With Catheter-related Infection.
Yamanaka S, Hiraide T, Momoi M, et al. · CJC Open 2026
- Treprostinil: Mechanism of Action, Clinical, and Translational Science.
Sameed M, Waleed M, Colomy V · Clin Transl Sci 2026
- Treprostinil Inhalation Powder for Pulmonary Arterial Hypertension: Evidence and Clinical Positioning Among Inhaled Formulations.
Bui PT, Ramos E, Hammer J, et al. · Ann Pharmacother 2026
- Phase 3 Antifibrotic-Directed Therapy Outcomes in Idiopathic Pulmonary Fibrosis: Beyond FVC Decline.
Kashizaki F, Watanabe S, Orii R, et al. · Lung 2026
Also in development for Interstitial Lung Disease
- MK-7240PRA023, TulisokibartPhase 310 trials
Merck & Co. · Ulcerative Colitis, Psoriatic Arthritis, Crohn's Disease
- INS1009Treprostinil PalmitilPhase 37 trials
Insmed Incorporated · Interstitial Lung Disease, Pulmonary Hypertension, Pulmonary Arterial Hypertension
- ATYR1923KRP-R120, EfzofitimodPhase 32 trials
aTyr Pharma, Inc. · Interstitial Lung Disease, Pulmonary Sarcoidosis
- MosliciguatPhase 32 trials
Pulmovant, Inc. · Pulmonary Hypertension, Interstitial Lung Disease, Vascular Diseases
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.